KR940013499A - 푸마길롤 유도체의 제약학적 안정 조성물 - Google Patents

푸마길롤 유도체의 제약학적 안정 조성물 Download PDF

Info

Publication number
KR940013499A
KR940013499A KR1019930028037A KR930028037A KR940013499A KR 940013499 A KR940013499 A KR 940013499A KR 1019930028037 A KR1019930028037 A KR 1019930028037A KR 930028037 A KR930028037 A KR 930028037A KR 940013499 A KR940013499 A KR 940013499A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
fatty acid
acid ester
fumagilol
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019930028037A
Other languages
English (en)
Korean (ko)
Inventor
시게오 야나이
가즈히로 사이또
히로아끼 오까다
Original Assignee
다께다 구니오
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 구니오, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 다께다 구니오
Publication of KR940013499A publication Critical patent/KR940013499A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
KR1019930028037A 1992-12-16 1993-12-16 푸마길롤 유도체의 제약학적 안정 조성물 Withdrawn KR940013499A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33582892 1992-12-16
JP92-335828 1992-12-16

Publications (1)

Publication Number Publication Date
KR940013499A true KR940013499A (ko) 1994-07-15

Family

ID=18292862

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930028037A Withdrawn KR940013499A (ko) 1992-12-16 1993-12-16 푸마길롤 유도체의 제약학적 안정 조성물

Country Status (8)

Country Link
US (1) US5422363A (https=)
EP (1) EP0602586B1 (https=)
KR (1) KR940013499A (https=)
CN (1) CN1093901A (https=)
AT (1) ATE153854T1 (https=)
CA (1) CA2111560A1 (https=)
DE (1) DE69311278T2 (https=)
PH (1) PH30120A (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5699244A (en) * 1994-03-07 1997-12-16 Monsanto Company Hand-held GUI PDA with GPS/DGPS receiver for collecting agronomic and GPS position data
US5566069A (en) * 1994-03-07 1996-10-15 Monsanto Company Computer network for collecting and analyzing agronomic data
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
US20010025046A1 (en) * 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
ES2286998T3 (es) 1999-02-26 2007-12-16 Sanofi-Aventis Formulacion estable que contiene fumagillina.
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
BR0115109A (pt) * 2000-11-01 2005-10-18 Praecis Pharm Inc Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
US7001603B2 (en) * 2001-02-28 2006-02-21 Color Access, Inc. Gelled two phase cosmetic compositions
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
WO2005066197A2 (en) * 2003-12-29 2005-07-21 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
EP2217283A2 (en) * 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
US8865746B2 (en) 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
CA2777108A1 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
US9173865B2 (en) 2010-11-29 2015-11-03 Zafgen, Inc. Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
MX344238B (es) 2011-01-26 2016-12-07 Zafgen Inc Compuestos de tetrazol y métodos para preparar y usar los mismos.
EP2683706B1 (en) 2011-03-08 2018-02-21 Zafgen, Inc. Oxaspiro [2.5]octane derivatives and analogs
EP2705036B1 (en) 2011-05-06 2015-08-12 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
CN103764641B (zh) 2011-05-06 2016-10-26 扎夫根股份有限公司 部分饱和的三环化合物及其制备和使用方法
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン，インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
BR112014027808A2 (pt) 2012-05-07 2017-06-27 Zafgen Inc sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
MX2014013599A (es) 2012-05-08 2015-05-11 Zafgen Inc Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
BR112014027981A2 (pt) 2012-05-09 2017-06-27 Zafgen Inc compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
AU2013337282A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds and methods of making and using same
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
IL300825A (en) 2017-03-15 2023-04-01 Cerecin Inc Pharmaceutical preparations with a high drug load of medium-length triglyceride chains and methods related thereto
BE1027390B1 (nl) 2019-06-21 2021-02-02 Nutrition Sciences Nv Mfca-samenstelling voor gebruik in de aquacultuur van schaaldieren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
KR0138530B1 (ko) * 1988-09-01 1998-05-15 우메모또 요시마사 푸마길롤 유도체
ES2053890T3 (es) * 1988-09-01 1994-08-01 Takeda Chemical Industries Ltd Agente inhibidor de la angiogenesis.
DE69001187T2 (de) * 1989-03-06 1993-07-08 Takeda Chemical Industries Ltd 6-epifumagillole, ihre herstellung und ihre verwendung.
EP0386667B1 (en) * 1989-03-06 1993-11-18 Takeda Chemical Industries, Ltd. 6-Amino-6-desoxyfumagillols, production and use thereof
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (https=) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.

Also Published As

Publication number Publication date
EP0602586A3 (https=) 1994-08-31
CA2111560A1 (en) 1994-06-17
DE69311278T2 (de) 1997-10-30
EP0602586A2 (en) 1994-06-22
US5422363A (en) 1995-06-06
ATE153854T1 (de) 1997-06-15
CN1093901A (zh) 1994-10-26
EP0602586B1 (en) 1997-06-04
DE69311278D1 (de) 1997-07-10
PH30120A (en) 1996-12-27

Similar Documents

Publication Publication Date Title
KR940013499A (ko) 푸마길롤 유도체의 제약학적 안정 조성물
US5714512A (en) Compositions containing taxane derivatives
US5698582A (en) Compositions containing taxane derivatives
DE69804624T2 (de) Selbstemulgierende formulierung enthaltend lipophile verbindungen
DE69823663T2 (de) Selbstemulgierbare formulierung enthaltend lipophile verbindungen
IT1281337B1 (it) Preparazione farmaceutica orale contenente ciclosporina come sostanza attiva ed un preconcentrato di emulsione multipla
KR850002953A (ko) 의약학적 제제의 제조방법
KR890011601A (ko) (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약
FI970634A0 (fi) Syklosporiinien uudet, suun kautta annettavat, koostumukseltaan yksinkertaiset valmistemuodot, joista biosaatavuus on hyvä, sekä menetelmä niiden valmistamiseksi
DK1273289T3 (da) Farmaceutiske sammensætninger indeholdende ascomycinderivater
KR840006440A (ko) 국소 외용 약학적 조성물의 제조방법
ES2076412T3 (es) Proceso para la fabricacion de microesferas.
GB2391471B (en) Pharmaceutical compositions
ATE101036T1 (de) Aktivitaetspotenziator gegen krebs.
JP2003503339A (ja) 抗癌剤を含有する自己乳化システム
EP0973710B1 (en) Omega-amino acid derivatives, processes of their preparation and their use
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
KR930702965A (ko) 생체이용성이 개선된 프로부콜 함유 제약 조성물
KR940701251A (ko) 콜레스테롤-강하 토코페롤 동족체
PT87704B (pt) Processo para a preparacao de composicoes farmaceuticas para administracao transdermica contendo um derivado de 1,4-di-hidropiridina
ATE69384T1 (de) Pharmazeutische zubereitung fuer die intrarektale verabreichung von calcitonin und daraus hergestellte einzeldosisformen.
DE3869256D1 (de) Jodierte ester.
KR940014279A (ko) 아이오드화 습윤제
GB1081551A (en) Injectable oil compositions
JPH09510722A (ja) 注射可能なジリスロマイシン溶液

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000